TORONTO, March 19, 2019 (GLOBE NEWSWIRE) -- Datametrex AI Limited (TSXV:DM) (the
“Company” or “Datametrex”) is pleased to provide update on its pilot program with EMPOWER CLINICS
INC. (CSE: EPW) (“Empower”) through its subsidiary Canntop AI Inc. (“Canntop”)
to develop a deeper understanding of patients’ awareness of cannabis-based treatment options and the ongoing effectiveness.
The Company has provided select SEO terms and phrases for use in Canntop AI platform targeting two key company
markets of Portland, OR and Phoenix, AZ to gain actionable insights on how consumer social data is generating interest in CBD based
products, alternative pain management options and the use of cannabis-based therapies.
These insights are beginning to show how patients in our key markets are talking about or describing their experience, ideas and
even providing recommendations about alternative therapies and its effectiveness in treating a wide array of qualifying conditions.
“We believe the outcomes of our AI efforts, if successful, could position the Company as an educational leader and we plan to
collaborate with the industry to ultimately improve patient care,” said Steven McAuley, Empower’s Chief Executive Officer.
“The powerful AI tools of Canntop are required to successfully analyze the substantial amounts of data in the Empower database and
the additional data from the proposed acquisition of the Sun Valley Clinic group, that has a combined 165,000 patients.”
“We are thrilled that Empower chose Canntop to be their partner for their Artificial Intelligence needs. This is a great validation
for our business model and we look forward to expanding our program with Empower as they continue to expand their product. We
believe that this alliance between Canntop and Empower will create a strong platform for data analysis in the Cannabis sector
especially in the U.S., providing insurers and health care providers an ideal solution for patient care,” says Michael Frank, the
Chief Strategy Officer of Datametrex.
About Empower
Empower is undertaking new growth initiatives to be positioned as a vertically integrated diverse health and
wellness company with an expanding network of physician-staffed clinics, a diverse CBD product strategy and a leader in
hemp-derived CBD extraction, research and development. Treatment solutions are focused on education, data and efficacy in
combination with other modalities to support patients with serious qualifying conditions, such as chronic pain, PTSD, sleep
disorders, opioid dependency, epilepsy and more. It is expected that Empower's proprietary product line “Sollievo” will offer
patients a variety of delivery methods of doctor recommended cannabidiol (CBD) based product options in its clinics, online and at
major retailers. With over 120,000 patients, an expanding clinic footprint, a focus on new technologies, including tele-medicine
and an expanded product development strategy, Empower is ready to capitalize on the explosive growth expectations in the United
States after the passing of US$867 billion Agriculture Improvement Act (the Farm Bill).
About Datametrex
Datametrex AI Limited is a technology focused company with exposure to Artificial Intelligence and Machine
Learning through its wholly owned subsidiary, Nexalogy (www.nexalogy.com) and Implementing Blockchain technology for secure Data Transfers through
its investee company, Graph Blockchain (www.graphblockchain.com).
For further information, please contact:
Jeffrey Stevens – President & COO
Phone: (647) 400-8494
Email: jstevens@datametrex.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains “forward-looking information” within the meaning of applicable securities
laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information.
In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”,
“should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms,
or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or
“will” happen, or by discussions of strategy.
Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and
not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date
of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such
forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information,
whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material
difference between subsequent actual events and such forward-looking information, except as required by applicable
law.
